Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1994-11-03
1997-10-21
Eisenschenk, Frank C.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
4241841, 536 231, A61K 4800, C12N 1512, C12N 1552
Patent
active
056796471
ABSTRACT:
The invention is directed to methods for introducing biologically active peptides into a host by administration of polynucleotides which operatively encode for the peptide of interest. In a preferred embodiment of the invention, a host who has been identified as having a tumor bearing at least one tumor-associated antigen is the recipient of a polynucleotide which operatively encodes for a foreign mimic of the tumor-associated antigen or a mutation of the self-antigen. The antigen-encoding polynucleotides are administered to host tissues which have a high concentration of antigen presenting cells in them relative to other host tissues. The method is particularly useful in treating cancer through induction of antigen-specific cytotoxic T lymphocytes in the host for lysis of tumor cells bearing the antigen. Devices and compositions for use in the methods of the invention are also described.
REFERENCES:
patent: 5580859 (1996-12-01), Felgner et al.
patent: 5589466 (1996-12-01), Felgner et al.
Chien, "Mucosal Drug Delivery: Potential Routes for Noninvasive Systemic Administration," Novel Drug Delivery Systems, vol. 50, pp. 197-227.
Chien, "Transdermal Drug Delivery and Delivery Systems," Novel Drug Delivery Systems, vol. 50, pp. 301-380.
Chien, "Nasal Drug Delivery and Delivery Systems," Novel Drug Delivery Systems, vol. 50, pp. 229-268.
Sloan, "Use of Solubility Parameters from Regular Solution Theory to Describe Partitioning-Driven Processes," Prodrugs: Topical and Ocular Drug Delivery, vol. 53, pp. 179-204.
Tice, et al., "Parenteral Drug Delivery: Injectables," Treatise on Controlled Drug Delivery, pp. 315-339.
Chang, et al., "Nasal Drug Delivery," Treatise on Controlled Drug Delivery, pp. 423-463.
Been, et al., "One Binding Site Determines Sequence Specificity of Tetrahymena Pre-rRNA Self Splicing, Trans-Splicing, and RNA Enzyme Activity," Cell, vol. 47, 207-216, Oct. 24, 1986.
Gillies, et al., "Expression of Human Anti-Tetanus Toxoid Antibody in Transfected Murine Myeloma Cells," Bio/Technology, vol. 7, Aug. 1989, pp. 799-804.
Ward et al., "Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli", Nature, vol. 341, 12 Oct. 1989, pp. 544-546.
Wolff, et al., "Conditions Affecting Direct Gene Transfer into Rodent Muscle In Vivo", BioTechniques vol. 11, No. 4 (1991), pp. 474-485.
Cohen, "Naked DNA Points Way to Vaccines," Science, vol. 259, 19 Mar. 1993, pp. 1691-1692.
Acsadi, et al., "Human dystrophin expression in mdx mice after intramuscular injection of DNA constructs," Nature, vol. 352, 29 Aug. 1991, pp. 815-818.
Wolff, et al., "Indirect Gene Transfer into Mouse Muscle in Vivo," Science, vol. 24, Mar. 1990, pp. 1465-1468.
Barr, et al., "Systemic Delivery of Recombinant Proteins by Genetically Modified Myoblasts," Science, vol. 254, Dec. 1991, pp. 1507-1512.
Ulmer, et al., "Heterologous Protection Against Influenza by Injection of DNA Encoding a Viral Protein," Science, vol. 259, 19 Mar. 1993, pp. 1745-1748.
"The Ultimate Delivery System: Lectro Patch Instructions," Advertisement by General Medical Company.
Kaplan, et al., "Rational Immunotherapy with Interleukin 2," Bio/Technology, vol. 10, Feb. 1992, pp. 157-162.
Caligiuri, et al., "Selective Modulation of Human Natural Killer Cells In Vivo After Prolonged Infusion of Low Dose Recombinant Interleukin 2," J. Clin. Invest., vol. 91, Jan. 1993, pp. 123-132.
Teppler, et al., "Prolonged Immunostimulatory Effect of Low-Dose Polyethylene Glycol Interleukin 2 in Patients with Human Immunodeficiency Virus Type 1 Infection," J. Exp. Med., vol. 177, Feb. 1993, 483-492.
Lotz, et al., Brief Definitive Report, J. Exp. Med., vol. 167, Mar. 1988, 1253-1258.
Robinson, et al., "Use of Direct DNA Inoculations to Elicit Protective Immune Responses," Journal of Cellular Biochemistry, Supp. 17D, 1993, p. 92.
Donohue, et al., "In Vivo Administration of Purified Jurkat-derived Interleukin 2 in Mice," Cancer Research, vol. 44, Apr. 1984, pp. 1380-1386.
Goldstein, et al., "Repetitive Weekly Cycles of Interleukin 2: Effect of Outpatient Treatment with a Lower Dose of Interleukin 2 . . . ," Cancer Research, vol. 49, pp. 6832-6839, Dec. 1, 1989.
Hefeneider, et al., "In Vivo Interleukin 2 Administration Augments the Generation of Alloreactive Cytolytic T Lymphocytes and Resident Natural Killer Cells," Journal of Immunology, vol. 130, No. 1, Jan. 1983, 222-227.
Stribling, et al., "Aerosol gene delivery in vivo," Proc. Natl. Acad. Sci. USA, vol. 89, pp. 11277-11281 Dec. 1992.
Del Rey, et al., "Antidiabetic effects of interleukin 1," Proc. Natl. Acad. Sci. USA, vol. 86, pp. 5943-5947, Aug. 1989.
Shields, et al., "Calorie restriction suppresses subgenomic mink cytopathic focus-forming murine leukemia virus transcription and frequency . . . ," Proc. Natl. Acad. Sci. USA, vol. 88, pp. 11138-11142, Dec. 1991.
Tang, et al., "Genetic immunization is a simple method for eliciting an immune response," Nature, vol. 356, 12 Mar. 1992, pp. 152-154.
Gorman, et al., "The Rous sarcoma virus long terminal repeat is a strong promoter when introduced into a variety of eukaryotic cells . . . ," Proc. Natl. Acad. Sci. USA, vol. 79, pp. 6777-6781, Nov. 1982.
Norton, et al., "Bacterial B-Galactosidase as a Marker of Rous Sarcoma Virus Gene Expression and Replication," Molecular and Cellular Biology, vol. 5, No. 2, Feb. 1985, pp. 281-290.
Krieg, et al., "Functional messenger RNAs are produced by SP6 in vitro transcription of cloned cDNAs," Nucleic Acids Research, IRL Press Limited, vol. 12, No. 18, 1984, pp. 7057-7070.
Huang, et al., "Role of Bone Marrow-Derived Cells in Presenting MHC Class 1-Restricted Tumor Antigens," Science, vol. 264, 13 May 1994, pp. 961-965.
Shastri, et al., "Endogenous Generation and Presentation of the Ovalbumin Peptide/K.sup.b Complex to T Cells," Journal of Immunology, vol. 150, No. 7, pp. 2724-2736, Apr. 1, 1993.
Liang, et al., "Differential Display of Eukaryotic Messenger RNA by Means of the Polymerase Chain Reaction," Science, vol. 257, 14 Aug. 1992, pp. 967-971.
Lisitsyn, et al., "Cloning the Differences Between Two Complex Genomes," Science, vol. 259, 12 Feb. 1993, pp. 946-951.
Israeli, et al., "Expression of the Prostate-specific Membrane Antigen," Cancer Res., 54:1807-1811 (1994).
Mamula, et al., "B Cells Process and Present Lupus Autoantigens that Initiate Autoimmune T Cell Responses," Journal of Immunology, 1994, 152:1453-1461.
Mader, et al., "A steroid-inducible promoter for the controlled overexpression f cloned genes in eukaryotic cells," Proc. Natl. Acad. Sci. USA, vol. 90, pp. 5603-5607, Jun. 1993.
Ferrara, et al., "Highly Potent Transcriptional Activation by 16-ene Derivatives of 1,25-Dihydroxyvitamin D.sub.3 ,", Journal of Biological Chemistry, vol. 269, No. 4, Jan. 18, 1994, pp. 2971-2981.
Carson Dennis A.
Raz Eyal
Eisenschenk Frank C.
The Regents of the University of California
LandOfFree
Methods and devices for immunizing a host against tumor-associat does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and devices for immunizing a host against tumor-associat, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and devices for immunizing a host against tumor-associat will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1006761